Russell Andrew Shelp

Title: Russell Andrew Shelp: Innovator in HER2 Mutation Inhibitors

Introduction

Russell Andrew Shelp is a notable inventor based in Boulder, CO (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target HER2 mutations. His work is crucial in the ongoing fight against cancer and abnormal cell growth.

Latest Patents

Shelp holds a patent for HER2 mutation inhibitors. This invention relates to compounds of Formula (I) and enantiomers thereof, as well as pharmaceutically acceptable salts of these compounds. The invention further encompasses pharmaceutical compositions that include such compounds and salts, along with methods and uses for treating abnormal cell growth, including cancer, in subjects in need.

Career Highlights

Russell Andrew Shelp is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His role at Pfizer allows him to leverage his expertise in drug development and innovation, contributing to advancements in cancer treatment.

Collaborations

Shelp has collaborated with notable colleagues, including Bryan Daniel Ellis and Erik James Hicken. These partnerships enhance the research and development efforts within the pharmaceutical sector.

Conclusion

Russell Andrew Shelp's work in developing HER2 mutation inhibitors represents a significant advancement in cancer treatment. His contributions to Pfizer Corporation and collaborations with fellow innovators underscore his impact on the pharmaceutical industry.